Swissmedic has granted marketing authorization for Octapharma’s new fibrinogen concentrate product fibryga for the treatment of congenital and acquired fibrinogen deficiencies.
AstraZeneca’s respiratory biologic Fasenra (benralizumab) has secured the orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA).
The Mundipharma network of independent associated companies has secured approval from the European Commission (EC) for its Pelmeg (pegfilgrastim) as a biosimilar treatment to reduce the duration of neutropenia and incidence of febrile neutropenia in adults treated with cytotoxic chemotherapy for malignancy for chemotherapy.
The European Commission (EC) has approved Camurus’ weekly and monthly Buvidal (prolonged release buprenorphine) for the treatment of opioid dependence in adults and adolescents from 16 years of age.
Spark Therapeutics and Novartis have secured the approval from the European Commission (EC) for their one-time gene therapy Luxturna (voretigene neparvovec) to treat patients with a rare inherited form of vision loss that could lead to blindness.
Pfizer has secured approval from the US Food and Drug Administration (FDA) for its Daurismo (glasdegib) to treat adult patients with newly-diagnosed acute myeloid leukemia (AML) for whom intensive chemotherapy is not an option.
Takeda Pharmaceutical has secured clearance from the European Commission (EC) for its proposed $62bn acquisition of Shire.
Dr. Reddy’s Laboratories said that the US Court of Appeals for the Federal Circuit issued a decision in its favor by concluding that Indivior had not shown that it is likely to succeed on the merits of its infringement case on US Patent No. 9,931,305.
Swedish Orphan Biovitrum (Sobi) and Novimmune have secured approval from the US Food and Drug Administration (FDA) for their monoclonal antibody Gamifant (emapalumab-lzsg) for the treatment of primary hemophagocytic lymphohistiocytosis (HLH).
The US Food and Drug Administration (FDA) has approved Aries Pharmaceuticals’ Aemcolo (rifamycin) 194mg delayed-release tablets, a new minimally-absorbed antibiotic that is delivered to the colon, for the treatment of adult patients with Travelers’ Diarrhea caused by non-invasive strains of Escherichia coli.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.